New call by the Novo Holding REPAIR Impact Fund: Let us write your proposal! The REPAIR Impact Fund invites companies and corporate spin-outs in Europe and the United States to submit projects addressing antibiotic resistance. Deadline: 15 May 2018.
Novo Holdings has established the REPAIR Impact Fund to replenish the anti-infective pipeline and to combat antimicrobial resistance. The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in companies involved in discovering and early-stage development of therapies targeting resistant microorganisms.
The fund is expected to invest USD 20 million to USD 40 million per year over 3–5 years in about 20 projects in Europe and the United States.
Immuno Valley has over 10 years experience in grant and funding application in the area of infectious diseases. We can give you customised advice and support during your application process for this and other funds.
- Contact us! to support you in writing a solid proposal.
- Deadline to submit: 15 May 2018
- More information: direct link to the Repair Impact Fund
- Watch the video:
Watch the animation video TRANSVAC2: European Network of Vaccine Research and Development
Watch the animation video TRANSVAC2: European Network of Vaccine Research and Development and help the TRANSVAC2 team win a competition. Like the video on Youtube. Hurry, likes to be received by 16 April at noon.
Launching new funding opportunities: NADP Vouchers. Available this spring, stay tuned.
Immuno Valley took the lead in designing a funding instrument to accelerate antibiotic and alternative therapy opportunities by the NADP, the Netherlands Antibiotic Development Platform.
Immuno Valley: driving force behind the new EXPLORA Program: Personalized diagnostics and interventions in chronic inflamatory diseases
Experienced research groups and clinicians, biotechs and multinational companies active in diagnostics, healthcare, nutrition and pharma are joined in a new program: EXPLORA. Immuno Valley played a major role in establishing the consortium and in applying for "Perspectief", the NWO grant.
ZonMW subsidy granted for the BEWARE Consortium
The BEWARE Consortium stands for Blueprint for Early Warning of Antimicrobial Resistance Emergence in animals. This early warning blueprint is unique and innovative because it takes account of the most likely routes of introduction, the transmission of AMR between animals and between farms and the diagnostic quality of the assays used.
Successful meetings at BIOEuropeSpring2018
Looking back at a great BIOEuropeSpring2018. We were able to update our valuable business relations and made new interesting connections in human and veterinary pharma to set up new Public Private Partnerships.